This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497
Crouse JR et al. (1985) Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 26: 566–574
Downs JR et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622
Otvos JD et al. (2002) Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 (Suppl 1): 22–29
Anonymous (online 3 August 2005) Labcorp to offer liposcience's NMR lipoprofile test. [http://www.liposcience.com/control.cfm?id=54&prid=40] (accessed 23 January 2006)
Austin MA et al. (1988) Low-density lipoprotein sub-class patterns and risk of myocardial infarction. JAMA 260: 1917–1921
Coresh J et al. (1993) Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res 34: 1687–1697
Stampfer MJ et al. (1996) A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276: 882–888
St-Pierre AC et al. (2005) Low-density lipoprotein subfractions and the long term risk of ischemic heart disease in men: 13 year follow up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25: 553–559
Campos H et al. (2001) Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 286: 1468–1474
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Consultant, speaker bureau or funded research from AstraZeneca, Merck, Schering Plough, Novartis, Sankyo.
Rights and permissions
About this article
Cite this article
Stein, E. Are LDL subclass measurements clinically relevant?. Nat Rev Endocrinol 2, 120–121 (2006). https://doi.org/10.1038/ncpendmet0112
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0112